Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Helen Leis

Partner, Health and Life Sciences, Oliver Wyman

An Analysis of Infection Odds Based on US County

Our new model projects the chance that within a gathering of random people, there's an active COVID-19 infection.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Timeline to Normalcy - Updated March 15, 2021

Our revised analysis and state-by-state outlook suggest the US may achieve pHIT in early summer if vaccinations align with a more optimistic scenario.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Timeline to Normalcy - Updated January 25, 2021

The journey to normalcy involves understanding and addressing many different factors. Our latest analysis suggests we are likely to achieve pHIT in the US on average in late summer.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Hospitals nationwide could near collapse as the pandemic straps them of necessary resources.

Partner & Co-Head – Risk & Public Policy, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

New Predictions on COVID-19 Vaccines and Herd Immunity

How COVID-19 case counts and vaccines may get us back to normalcy by June.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

New Oliver Wyman analysis on when and how a vaccine may be available and key considerations for how to reach herd immunity.

CEO, Independent Grocers Alliance
Partner, Health and Life Sciences, Oliver Wyman

The nation's new "normal" may not come until Q4 of 2021. Companies must consider what is sustainable and where to adjust for the long haul.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Returning to work, school, and daily life in a recovering economy means co-existing with COVID-19.

Partner, Health and Life Sciences, Oliver Wyman
Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner and Co-Lead of Digital Transformation, EMEA, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Q&A with a Pandemic Response Expert

How COVID-19 testing, contact tracing, and targeted quarantine may revive consumer and employee confidence.

Partner, Health and Life Sciences, Oliver Wyman

As parts of the nation begin to re-open, new considerations are unfolding that leaders struggle to manage.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe